Sona NanotechSNANF 26 Current Ratio is 0.20 as of Jan. 2026, which is 59% below its 10-year median of 0.49. GuruFocus rates SNANF with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 214 Medical Diagnostics & Research companies, Sona Nanotech ranks worse than 94.86% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sona Nanotech's current ratio for the quarter that ended in Jan. 2026 was 0.20.
Sona Nanotech has a current ratio of 0.20. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Sona Nanotech has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Sona Nanotech's Current Ratio or its related term are showing as below:
SNANF'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.49 Max: 2.56
Current: 0.2
During the past 13 years, Sona Nanotech's highest Current Ratio was 2.56. The lowest was 0.01. And the median was 0.49.
SNANF's Current Ratio is ranked worse than 94.86% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs SNANF: 0.20
Sona Nanotech (OTCPK:SNANF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sona Nanotech Current Ratio Related Terms
Sona Nanotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Sona Nanotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Sona Nanotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sona Nanotech Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sona Nanotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sona Nanotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sona Nanotech (SNANF) has a Current Ratio of 0.20 as of Jan. 2026. This is 59% below median its historical median of 0.49. Over the past decade, Sona Nanotech's Current Ratio has ranged from 0.01 to 2.56. According to the industry distribution chart, Sona Nanotech ranks #203 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 94.9%.
Is Sona Nanotech's Current Ratio too high?
Sona Nanotech's current Current Ratio of 0.20 is 59% below median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.56. The Medical Diagnostics & Research industry median Current Ratio is 2.06. Sona Nanotech's value of 0.20 is 90.3% below this industry median. Based on the distribution chart, Sona Nanotech ranks #203 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sona Nanotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Sona Nanotech's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sona Nanotech ranks #203 out of 214 companies for Current Ratio. This places Sona Nanotech in the lower half of its industry. The industry median Current Ratio is 2.06. Sona Nanotech's value of 0.20 is 90.3% below this benchmark. Historically, Sona Nanotech's own Current Ratio has ranged from 0.01 to 2.56 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 2.06, Sona Nanotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.06, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sona Nanotech's current Current Ratio of 0.20 is 90.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sona Nanotech's current Current Ratio is 0.20, which is 59% below median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sona Nanotech stock overvalued right now?
Sona Nanotech (SNANF) has a current Current Ratio of 0.20. The current Current Ratio is 0.20, which is 59% below median its 10-year median of 0.49 and 90.3% below the Medical Diagnostics & Research industry median of 2.06. Sona Nanotech's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sona Nanotech (SNANF), the current Current Ratio is 0.20 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sona Nanotech Inc is involved in the nanotechnology life sciences industry. It has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles and is engaged in the research and development of its proprietary technology for use in biomedical applications and multiplex diagnostic testing platforms. The company is using its gold nano rods manufacturing technology to develop new products and methods for cancer treatment, including a Targeted Hyperthermia Therapy (THT). Additionally, it has filed patent applications in the U.S. regarding a gold nanorod conjugation concept for targeted drug delivery, combination therapies for treating cancer, and for an endoscope with an optical fibre and thermal sensor for photothermal therapy.
26GF Score
Get the complete analysis for SNANF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNANF has been successfully added to your 
